This study provides key subgroup evidence for immunotherapy combinations in advanced cervical cancer, particularly demonstrating significant benefits in patients with low PD-L1 expression and those ineligible for bevacizumab, suggesting that Cadonilimab, as a bispecific antibody, may overcome current limitations of immunotherapy and offer insights into mechanisms of resistance to immune checkpoint inhibitors.
Literature Overview
This article, 'Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial,' published in Nature Communications, systematically investigates the consistency of efficacy of the PD-1/CTLA-4 bispecific antibody Cadonilimab combined with chemotherapy ± bevacizumab across different patient subgroups in the first-line treatment of advanced cervical cancer. Based on pre-specified subgroup analyses from the phase 3 COMPASSION-16 trial, this study further validates the robustness of the primary endpoints and provides high-level evidence for clinical individualized decision-making.Background Knowledge
Cervical cancer is the fourth most common malignant tumor among women worldwide, with a very poor prognosis for patients with advanced or metastatic disease, who have a median overall survival of only 13–17 months. Although PD-L1 expression is an important biomarker for current immunotherapies, the KEYNOTE-826 study showed that pembrolizumab significantly extends survival only in patients with PD-L1 CPS ≥1, leaving those with PD-L1-negative tumors without effective immunotherapy options. Additionally, approximately 40% of patients cannot receive bevacizumab due to contraindications, further limiting treatment choices. The current bottleneck in immune checkpoint inhibitor research lies in how to overcome PD-L1 expression dependency, limited efficacy of monotherapy, and toxicity associated with combination therapies. Cadonilimab, the first PD-1/CTLA-4 bispecific antibody globally to enter phase 3 clinical trials, theoretically enhances T-cell activation and infiltration by simultaneously blocking the PD-1 and CTLA-4 pathways, potentially achieving broader antitumor activity in tumors with low PD-L1 expression or a highly immunosuppressive microenvironment. This study systematically evaluates the consistency of Cadonilimab’s efficacy across subgroups, aiming to provide new strategies for patients with unmet clinical needs.
Research Methods and Experiments
This study is based on the multicenter, double-blind, placebo-controlled phase 3 COMPASSION-16 trial, which enrolled 445 treatment-naïve patients with persistent, recurrent, or metastatic cervical cancer, randomly assigned in a 1:1 ratio to receive Cadonilimab plus chemotherapy ± bevacizumab or placebo. The primary analysis set was the full analysis set (FAS), with subgroup analyses performed using the Kaplan-Meier method and Cox regression models to evaluate progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). Subgroups included bevacizumab use, prior concurrent chemoradiotherapy (CCRT), PD-L1 CPS (<1, ≥1, ≥10), baseline metastatic status, choice of platinum agent, and age (<65 vs ≥65 years). PFS was assessed by a central blinded independent review (BICR) to ensure objective endpoint evaluation. All patients received standard chemotherapy (paclitaxel + cisplatin/carboplatin), and the study design adequately controlled for potential confounding factors through stratified randomization for bevacizumab use and prior CCRT status.Key Conclusions and Perspectives
Research Significance and Prospects
This study brings important changes to the treatment landscape of advanced cervical cancer. The broad efficacy of Cadonilimab supports its use as a universal first-line regimen, particularly filling the therapeutic gap for patients with PD-L1-negative tumors and those intolerant to bevacizumab. Its bispecific mechanism may reshape the tumor microenvironment and enhance T-cell responses, offering new strategies to overcome immunotherapy resistance. Future research should further explore its potential in combination with other therapies, such as PARP inhibitors or therapeutic vaccines.
Conclusion
The subgroup analysis of COMPASSION-16 establishes Cadonilimab plus chemotherapy ± bevacizumab as a strong first-line treatment option for advanced cervical cancer. The significant benefits observed in patients with PD-L1-negative status, older age, or contraindications to bevacizumab highlight the unique advantages of bispecific antibodies in overcoming current limitations of immunotherapy. This study not only provides evidence for individualized clinical practice but also advances our understanding of tumor immune microenvironment heterogeneity. From bench to bedside, this achievement marks a move toward a more precise and inclusive era in cervical cancer treatment. Future efforts should focus on identifying predictive biomarkers to optimize patient selection and evaluating long-term safety and quality of life to fully establish its foundational role in cervical cancer care.
